about the author

ENDPOINTS

editor@endpointsnews.com

author articles

Charles Ban­croft makes quick leap from Bris­tol My­ers ex­ec team to GSK; Medicxi adds two new part­ners to its team

6 years ago
Peer Review

Bio­gen sues com­pa­ny al­leged­ly sell­ing ad­u­canum­ab copy­cat; J&J takes on No­var­tis' MS fran­chise

6 years ago
News Briefing

In­sil­i­co inks an­oth­er deal with Sino Bio­phar­ma unit; Ra­maswamy's Data­vant to in­vest in the "pa­tient jour­ney"

6 years ago
News Briefing

Rick Klaus­ner's Lyell part­ners, helps fund Eu­reka's work on cell ther­a­pies; Blue­print bounces high­er on PhII

6 years ago
News Briefing

Cure­Vac’s In­g­mar Ho­err tells us why he re­turned to take on a pan­dem­ic; NGM los­es a pres­i­dent

6 years ago
Peer Review

Bris­tol My­ers scores new FDA nod for Op­di­vo/Yer­voy com­bo; US Army wants Gilead­'s po­ten­tial Covid-19 drug for in­fect­ed ...

6 years ago
News Briefing

Sy­neos up for sale — re­port; Takeda's Nin­laro fails PhI­II in mul­ti­ple myelo­ma; EMA braces for drug short­age

6 years ago
News Briefing

In­ovio files for $50M of­fer­ing amid Covid-19 vac­cine hunt; Zy­dus Cadi­la signs on with XO­MA on IL-2 deal

6 years ago
News Briefing

Coro­n­avirus up­date: Trump signs $8.3B spend­ing bill in­to law; Pfiz­er con­sid­ers mR­NA vac­cine pact with BioN­Tech

6 years ago
News Briefing

Abrax­ane de­vel­op­er Igle­sias joins Sen­ti Bio­sciences; AB2Bio re­cruits CEO

6 years ago
Peer Review

Bris­tol-My­ers joins forces with dig­i­tal ther­a­peu­tics co; Wear­able car­diovert­er de­fib­ril­la­tor scores $145M+ in Se­ries ...

6 years ago
News Briefing

Af­ter the field left her be­hind, a sci­en­tist-turned-in­vestor gets her first R&D job; Nous­com finds new lead­er­ship for ...

6 years ago
Peer Review

Sage con­firms sus­pen­sion of 2 de­pres­sion tri­als af­ter PhI­II flop; Es­pe­ri­on fol­lows up maid­en ap­proval with com­bo OK

6 years ago
News Briefing

Scott Got­tlieb in the run­ning for pos­si­ble coro­n­avirus czar; The drug Van­da sued the FDA over fails a piv­otal study

6 years ago
News Briefing

IDO-de­rived can­cer vac­cine scores in com­bo tri­al with Keytru­da; Vir teams up with WuXi on coro­n­avirus an­ti­bod­ies

6 years ago
News Briefing

Gen­fit de­lays high-stakes PhI­II NASH read­out; Bris­tol-My­ers grabs first Op­di­vo OK in esophageal can­cer

6 years ago
News Briefing

Heron's Ground­hog Day; Vi­for forms JV with Fre­se­nius Kabi in Chi­na

6 years ago
News Briefing

In­cyte's top­i­cal Jakafi scores again in eczema Phase III; Pri­or­i­ty re­view lines Roche's Tecen­triq up for new lung ...

6 years ago
News Briefing

Two fast track des­ig­na­tions for Corey Good­man's new start­up; Vi­for/Ake­bia se­cure pri­or­i­ty re­view vouch­er

6 years ago
News Briefing

As­traZeneca sweeps two can­cer drugs to the scrap heap; Epizyme nabs pri­or­i­ty re­view for sec­ond rare can­cer NDA

6 years ago
News Briefing

Elan­co grabs $140M in deal with French phar­ma com­pa­ny; An­oth­er com­pa­ny an­nounces a coro­n­avirus vac­cine hunt

6 years ago
News Briefing
Coronavirus

The Wuhan coro­n­avirus has an of­fi­cial name: COVID-19; Rev­o­lu­tion Med­i­cines up­sizes IPO terms

6 years ago
News Briefing
Coronavirus

Omega-backed start­up sells it­self qui­et­ly; Ab­b­Vie breaks out more Rin­voq da­ta; Re­vance gets FDA date for Botox ri­val

6 years ago
News Briefing

Cure­Vac jumps in­to coro­n­avirus vac­cine race; EMA backs raft of drugs, in­clud­ing No­vo Nordisk, Es­pe­ri­on com­pounds

6 years ago
News Briefing
Coronavirus
First page Previous page 13141516171819 Next page Last page
A service from the Financial Times